All Data
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): FTH1
Therapeutic Area: Hematology Product Name: BioFe
Highest Development Status: Undisclosed Product Type: Large molecule
Partner/Sponsor/Collaborator: SRS Life Sciences Pte ltd
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Agreement October 13, 2020
Details:
The agreement provides SRS exclusive rights for sales, marketing, and distribution of Sidero’s patented biologic iron, BioFeTM, for the management of iron deficiency and related disorders in India and Southeast Asia.
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): VMX-COO1
Therapeutic Area: Hematology Product Name: VMX-COO1
Highest Development Status: Undisclosed Product Type: Large molecule
Partner/Sponsor/Collaborator: Ysios Capital
Deal Size: $36.6 million Upfront Cash: Undisclosed
Deal Type: Series B Financing July 08, 2020
Details:
Proceeds to be used to achieve clinical proof of concept for lead compound, VMX-COO1, advance program to registrational studies, accelerate manufacturing trajectory towards commercial scale, and advance the discovery platform program.
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): Abelacimab
Therapeutic Area: Hematology Product Name: Undisclosed
Highest Development Status: Undisclosed Product Type: Large molecule
Partner/Sponsor/Collaborator: Anthos Therapeutics
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Partnership June 11, 2020
Details:
The agreement furthers Anthos Therapeutics mission to develop Abelacimab for patients at risk of thrombotic events, which are currently underserved by conventional anti-coagulant therapies.
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): Hematopoietic stem cells
Therapeutic Area: Hematology Product Name: Undisclosed
Highest Development Status: Undisclosed Product Type: Cell and Gene therapy
Partner/Sponsor/Collaborator: Baize Plan Fund
Deal Size: $3.6 million Upfront Cash: Undisclosed
Deal Type: Collaboration May 28, 2020
Details:
Through the project, sponsored by the Baize Plan Fund, the Ying laboratory aims to develop conditions for the long-term ex vivo expansion of mouse and human hematopoietic stem and progenitor cells.
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): Heparin Sodium
Therapeutic Area: Hematology Product Name: Undisclosed
Highest Development Status: Undisclosed Product Type: Small molecule
Partner/Sponsor/Collaborator: Cerus DMCC
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Acquisition April 29, 2020
Details:
Transaction enables Opocrin to become a leading global producer of active biologics including heparin and heparinoids.